Table V.
Review of previous reports.
| Reference | Year | Subjects | CMV positive rate |
Progression (%) | Late-onset (%) | Study design | Diagnostic methods | Country | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total | Bilateral | Unilateral | ||||||||
| Barbi et al. [12] | 2003 | >40 dB HL | 9/79 (11.4%) | 1/37 (2.7%) | 8/42 (19%) | NR | NR | Retrospective | DBS, qPCR | Italy |
| Ogawa et al. [3] | 2007 | >20 dB, nonsyndromic SNHL | 10/67 (10.5%) | 9/63 (14.3%) | 1/4 (25%) | NR | NR | Retrospective | UC, PCR | Japan |
| Samileh et al. [15] | 2008 | >40 dB HL | 33/95 (34.7%) | NR/75 | NR/20 | NR | NR | Prospective | Serologic test | Iran |
| Stehel et al. [16] | 2008 | NHS refer | 16/256 (6%) | 16/256 (6%) | NR | NR | NR | Prospective | DNA from urine | USA |
| Walter [20] | 2008 | Unexplained SNHL | 8/35 (22.9%) | NR | NR | NR | NR | Retrospective | DBS, qPCR | UK |
| Mizuno [21] | 2008 | Only bilateral | 3/45 (6.7%) | 3/45 (6.7%) | 0 | NR | NR | Prospective | UC, qPCR | Japan |
| Jakubikova et al. [14] | 2009 | >60 dB HL, NHS refer | 4/71 (5.6%) | 4/55 (7.3%) | 0/16 (0%) | NR | NR | Prospective | Serologic test | Slovak Republic |
| Boudewyns [22] | 2009 | NHS refer, >20 dB | 4/55 (7.3%) | NR | NR | NR | NR | Retrospective | DBS, qPCR | Belgium |
| Choi [23] | 2009 | NHS refer | 13/479 (2.7%) | 13/479 (2.7%) | NR | NR | NR | Retrospective | DBS, qPCR | USA |
| Tagawa [24] | 2009 | >70 dB, deaf schoolchildren | 3/26 (11.5%) | 3/26 (11.5%) | 0 (0%) | 2 (7.7%) | 1 (3.9%) | Retrospective | UC, qPCR | Japan |
| Kimani [25] | 2010 | NHS refer | 11/109 (10.1%) | 8/92 (8.8%) | 3/17 (17.6%) | NR | NR | Retrospective | DBS, qPCR | USA |
| Adachi [26] | 2010 | NHS refer, >35 dB, bilateral | 13/77 (17%) | 13/77 (17%) | 0 | NR | NR | Retrospective | UC, qPCR | Japan |
NR, not reported; DBS, dried blood spot; UC, umbilical cord; qPCR, quantitative PCR.